Projects per year
Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Personal profile
Member, Institute for Human Infections & Immunity
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where David Beasley is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Oxford JUNV Vaccine GP Study
Beasley, D. (PI)
University of Oxford ( Award # )
3/1/25 → 2/28/26
Project: Research project
-
PCMID 2024 -- Task Order A06
Beasley, D. (PI)
National Institute of Allergy and Infectious Diseases ( Award #75N93024D00042)
8/30/24 → 6/30/25
Project: Research project
-
Recombinant WNV vaccine adjuvanted with SLA-LSQ
Beasley, D. (PI)
Hawaii Biotech, Inc ( Award #75N93022C00034)
2/1/23 → 7/5/25
Project: Research project
-
Assays in Support of Filovirus Nonhuman Primate Studies for Advancement of Medical
Beasley, D. (PI)
Battelle Memorial Institute ( Award #HHSO100201700011I)
2/10/22 → 12/31/25
Project: Research project
-
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages
Kosulin, K., Brasel, T., Smith, J., Torres, M., Bitzer, A., Dubischar, K., Buerger, V., Mader, R., Weaver, S., Beasley, D. W. C. & Hochreiter, R., 2025, In: Emerging Microbes and Infections. 14, 1, 2469653.Research output: Contribution to journal › Article › peer-review
Open Access -
Zika virus: advancing a priority research agenda for preparedness and response
Zika Expert Workgroup, 2025, (Accepted/In press) In: The Lancet Infectious Diseases.Research output: Contribution to journal › Review article › peer-review
3 Scopus citations -
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
Zika Expert Workgroup, 2025, (Accepted/In press) In: The Lancet Infectious Diseases.Research output: Contribution to journal › Review article › peer-review
3 Scopus citations -
Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease
Johnson, D., Juelich, T., Zhang, L., Smith, J. K., Kalveram, B., Perez, D., Smith, J., Grimes, M. R., Garron, T., Torres, M., Massey, S., Brasel, T., Beasley, D. W. C., Freiberg, A. N. & Comer, J., Jul 2024, In: Viruses. 16, 7, 1101.Research output: Contribution to journal › Article › peer-review
Open Access -
Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model
Lawrence, W. S., Peel, J. E., Slayden, R. A., Peterson, J., Baze, W. B., Hensel, M. E., Whorton, E. B., Beasley, D. W. C., Cummings, J. E. & Macias-Perez, I., Jul 9 2024, In: Antimicrobial agents and chemotherapy. 68, 7, p. e0011224Research output: Contribution to journal › Article › peer-review
Open Access